Logo image of TLRY.CA

TILRAY BRANDS INC (TLRY.CA) Stock Fundamental Analysis

TSX:TLRY - US88688T1007 - Common Stock

1.89 CAD
-0.13 (-6.44%)
Last: 8/29/2025, 7:00:00 PM
Fundamental Rating

2

TLRY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 35 industry peers in the Pharmaceuticals industry. TLRY has a bad profitability rating. Also its financial health evaluation is rather negative. TLRY is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TLRY has reported negative net income.
TLRY had a negative operating cash flow in the past year.
TLRY had negative earnings in each of the past 5 years.
TLRY had negative operating cash flow in 4 of the past 5 years.
TLRY.CA Yearly Net Income VS EBIT VS OCF VS FCFTLRY.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500M -1B -1.5B -2B

1.2 Ratios

The Return On Assets of TLRY (-105.42%) is worse than 85.71% of its industry peers.
TLRY has a Return On Equity of -144.68%. This is amonst the worse of the industry: TLRY underperforms 80.00% of its industry peers.
Industry RankSector Rank
ROA -105.42%
ROE -144.68%
ROIC N/A
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
TLRY.CA Yearly ROA, ROE, ROICTLRY.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 -200 -300

1.3 Margins

The Gross Margin of TLRY (29.29%) is comparable to the rest of the industry.
TLRY's Gross Margin has improved in the last couple of years.
TLRY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.37%
GM growth 5YN/A
TLRY.CA Yearly Profit, Operating, Gross MarginsTLRY.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
TLRY has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TLRY has more shares outstanding
The debt/assets ratio for TLRY is higher compared to a year ago.
TLRY.CA Yearly Shares OutstandingTLRY.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
TLRY.CA Yearly Total Debt VS Total AssetsTLRY.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

TLRY has an Altman-Z score of -1.20. This is a bad value and indicates that TLRY is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.20, TLRY is not doing good in the industry: 62.86% of the companies in the same industry are doing better.
TLRY has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.19, TLRY perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z -1.2
ROIC/WACCN/A
WACC9.14%
TLRY.CA Yearly LT Debt VS Equity VS FCFTLRY.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

2.3 Liquidity

TLRY has a Current Ratio of 2.46. This indicates that TLRY is financially healthy and has no problem in meeting its short term obligations.
TLRY has a Current ratio (2.46) which is in line with its industry peers.
A Quick Ratio of 1.49 indicates that TLRY should not have too much problems paying its short term obligations.
TLRY has a Quick ratio (1.49) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.46
Quick Ratio 1.49
TLRY.CA Yearly Current Assets VS Current LiabilitesTLRY.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

TLRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -490.77%.
The Revenue has been growing slightly by 4.11% in the past year.
Measured over the past years, TLRY shows a very strong growth in Revenue. The Revenue has been growing by 37.52% on average per year.
EPS 1Y (TTM)-490.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3150%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y9.33%
Revenue growth 5Y37.52%
Sales Q2Q%-2.33%

3.2 Future

Based on estimates for the next years, TLRY will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.55% on average per year.
TLRY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.43% yearly.
EPS Next Y92.7%
EPS Next 2Y39.41%
EPS Next 3Y25.99%
EPS Next 5Y15.55%
Revenue Next Year3.8%
Revenue Next 2Y4.23%
Revenue Next 3Y4.38%
Revenue Next 5Y4.43%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TLRY.CA Yearly Revenue VS EstimatesTLRY.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TLRY.CA Yearly EPS VS EstimatesTLRY.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 2031 2032 0 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TLRY. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TLRY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLRY.CA Price Earnings VS Forward Price EarningsTLRY.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30 40

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TLRY is on the same level as its industry peers.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 59.08
TLRY.CA Per share dataTLRY.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as TLRY's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.41%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

TLRY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TILRAY BRANDS INC

TSX:TLRY (8/29/2025, 7:00:00 PM)

1.89

-0.13 (-6.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-28 2025-07-28/amc
Earnings (Next)10-08 2025-10-08/bmo
Inst Owners9.13%
Inst Owner ChangeN/A
Ins Owners0.29%
Ins Owner ChangeN/A
Market Cap2.08B
Analysts73.33
Price Target1.36 (-28.04%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2749.13%
Min EPS beat(2)-5362.97%
Max EPS beat(2)-135.29%
EPS beat(4)0
Avg EPS beat(4)-1413.07%
Min EPS beat(4)-5362.97%
Max EPS beat(4)-8.93%
EPS beat(8)1
Avg EPS beat(8)-730.51%
EPS beat(12)1
Avg EPS beat(12)-762.79%
EPS beat(16)3
Avg EPS beat(16)-613.4%
Revenue beat(2)0
Avg Revenue beat(2)-10.25%
Min Revenue beat(2)-13.28%
Max Revenue beat(2)-7.23%
Revenue beat(4)0
Avg Revenue beat(4)-8.93%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)-4.66%
Revenue beat(8)0
Avg Revenue beat(8)-5.77%
Revenue beat(12)1
Avg Revenue beat(12)-3.94%
Revenue beat(16)1
Avg Revenue beat(16)-4.24%
PT rev (1m)-25.25%
PT rev (3m)-23.65%
EPS NQ rev (1m)35.71%
EPS NQ rev (3m)25%
EPS NY rev (1m)40%
EPS NY rev (3m)30%
Revenue NQ rev (1m)-0.47%
Revenue NQ rev (3m)-4.16%
Revenue NY rev (1m)-1.38%
Revenue NY rev (3m)-3.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.84
P/FCF N/A
P/OCF N/A
P/B 1
P/tB 2.05
EV/EBITDA 59.08
EPS(TTM)-2.11
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS1.03
BVpS1.89
TBVpS0.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -105.42%
ROE -144.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.29%
FCFM N/A
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.37%
GM growth 5YN/A
F-Score4
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA 11.15
Cap/Depr 24.66%
Cap/Sales 4.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.46
Quick Ratio 1.49
Altman-Z -1.2
F-Score4
WACC9.14%
ROIC/WACCN/A
Cap/Depr(3y)21.23%
Cap/Depr(5y)65.02%
Cap/Sales(3y)3.68%
Cap/Sales(5y)7.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-490.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3150%
EPS Next Y92.7%
EPS Next 2Y39.41%
EPS Next 3Y25.99%
EPS Next 5Y15.55%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y9.33%
Revenue growth 5Y37.52%
Sales Q2Q%-2.33%
Revenue Next Year3.8%
Revenue Next 2Y4.23%
Revenue Next 3Y4.38%
Revenue Next 5Y4.43%
EBIT growth 1Y-11.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.68%
EBIT Next 3Y29.62%
EBIT Next 5Y17.51%
FCF growth 1Y-111.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-206.1%
OCF growth 3YN/A
OCF growth 5YN/A